Wednesday, April 2, 2025

Wednesday, April 2, 2025

Latest News

HORIZON THERAPEUTICS: Announces U.S. FDA Acceptance of its New Drug Application to Make PROCYSBI® (Cysteamine Bitartrate) Available as Oral Granules in Packets

Horizon Therapeutics plc (Nasdaq: HZNP) announced that the U.S. Food and Drug Administration (FDA) has accepted Horizon’s New Drug Application (NDA) for PROCYSBI® (Cysteamine Bitartrate) Delayed-Release Oral Granules in Packets.

U.S. FOOD AND DRUG ADMINISTRATION: Federal judge enters consent decree against Arkansas food and medical product grocery warehouse for insanitary conditions

The U.S. District Court for the Western District of Arkansas ordered J and L Grocery, LLC. of Alma, Arkansas, the company’s owner, James T. White, and its manager, Lori A. Layne, to stop distributing food, drug products, medical devices and cosmetics until the company complies with the Federal Food, Drug, and Cosmetic Act (FD&C Act) and other requirements listed in a consent decree.

Q'APEL MEDICAL: Announces FDA Clearance for Walrus Balloon Guide Catheter

Q'Apel Medical announced that it received U.S. Food and Drug Administration clearance for its novel walrus Balloon Guide Catheter (BGC).

MEMORIALCARE: Joins Innovative Effort to Solve Nation's Drug Shortage

Civica Rx partnership helps ensure essential, affordable, accessible generic medicines

NOVARTIS PHARMACEUTICALS CORPORATION: FDA accepts file and accelerates review of Novartis sickle cell disease medicine crizanlizumab (SEG101)

FDA grants crizanlizumab Priority Review based on Phase II data showing prevention of vaso-occlusive crises (VOCs) in patients with sickle cell disease, shortening FDA review to six months from standard ten months

SIMULATIONS PLUS: Enters into New Research Collaboration Agreement with the FDA

Center for Veterinary Medicine to apply GastroPlus® to assess product bioequivalence in canines

NOVADOZ PHARMACEUTICALS: MSN Labs/Novadoz Pharmaceuticals Early Success Continues With FDA Approval Of Generic Abiraterone

MSN Labs, the parent company of Novadoz Pharmaceuticals, was granted FDA approval to market Abiraterone Acetate 250mg tablets, a generic version of Janssen Pharmaceuticals' product Zytiga©, on July 9th.

HALOZYME THERAPEUTICS, INC.: Halozyme Announces Janssen Submits BLA To FDA For Subcutaneous Formulation Of DARZALEX® Utilizing ENHANZE® Technology

Halozyme Therapeutics, Inc. (NASDAQ: HALO), a biotechnology company developing novel oncology and drug-delivery therapies, today announced that its collaborator Janssen Biotech, Inc. (Janssen) has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration for the subcutaneous delivery of DARZALEX® (daratumumab) for patients with multiple myeloma.

NEOVASC, INC.: Neovasc to Explore HDE Approval Pathway and Alternate Trial Designs for the Reducer Following Guidance from the FDA

Neovasc Inc. ("Neovasc" or the "Company") (NASDAQ: NVCN)(TSX: NVCN), a leader in the development of minimally invasive transcatheter mitral valve replacement technologies and in the development of minimally invasive devices for the treatment of refractory angina, announced that the Food and Drug Administration ("FDA") has provided guidance to the Company following its Sprint Discussion on June 26, 2019, together with the Company's consultants and supporting U.S. cardiologists to review the clinical evidence collected to date for the Neovasc Reducer™ (the "Reducer"), to determine the most expedient pathway to potentially gaining regulatory approval in the United States and the quickest path to the U.S. market for these patients with an unmet need.

TSG CONSULTING: Urges Medical Device Manufacturers to Take Advantage of FDA's Pre-sub Meeting Program

With the majority of 510(k) submissions having major deficiencies or being rejected the first time, scientific and regulatory experts TSG Consulting recommend that manufacturers schedule a Pre-Submission (Pre-Sub) meeting with the FDA to improve the likelihood of the medical device being approved for sale in the US market.

NATIONAL INDUSTRIAL HEMP COUNCIL: Food and Drug Administration (FDA) to Speak at National Industrial Hemp Council (NIHC) 2019 Hemp Business Summit

The NIHC is pleased to announce Lowell Schiller as a keynote speaker at the National Industrial Hemp Council's 2019 Business Summit.

MOLECULIN BIOTECH, INC.: Files for New Patents for Annamycin After Receiving FDA Approval of Fast Track Designation

Moleculin Biotech, Inc. (Nasdaq: MBRX) ("Moleculin" or the "Company"), a clinical stage pharmaceutical company with a broad portfolio of drug candidates targeting highly resistant tumors, today announced it has filed new patents covering the production and reconstitution of Annamycin, which is currently in two clinical trials for the treatment of relapsed or refractory acute myeloid leukemia (AML).

KOIOS MEDICAL: FDA Clears Koios DS™ Breast 2.0 to Assist Physicians with AI-Based Software

Koios Medical, Inc has received 510(k) clearance from the U.S. Food and Drug Administration for Koios DS (Decision Support) Breast 2.0, a new version of its machine learning based platform that assists physicians in the classification and diagnosis of breast cancer.

ANATOMAGE: Releases Anatomage Cloud Platform Featuring One-Click Review to Provide HIPAA Compliant, FDA Approved Free DICOM Sharing and Medical Image Viewing

Anatomage Inc., a market leader in 3D medical imaging technology, released an update to the Anatomage Cloud platform that allows medical and dental professionals to quickly send 3D DICOM volumetric data to colleagues for one-click review.

ICOTEC MEDICAL: icotec AG Granted FDA Clearance To Market VADER®one Pedicle Screw System

icotec AG, a Swiss company, today announced the VADER®one pedicle screw system was granted U.S. Food and Drug Administration (FDA) 510(k) clearance for both minimally-invasive and open spine surgical procedures.

FDA Reporter